Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 893

Dr Nitin Jain - MD Anderson Cancer Centre, Houston, USA

Dr Nitin Jain speaks to ecancer at ASH 2018 about the trial looking at the combination of nivolumab and ibrutinib for patients with Richter transformation.

He reports that 42% of 24 patients had a response to the therapy and that 4 of the patients that had a response were then able to have an allotransplant.

Dr Jain explains that, although immune toxicity was a worry, very minimal toxicity was seen and the only side effects were from ibrutinib which they are accustomed to.

Related videos

follow us

Core Surgical Training

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation